Santhera Pharmaceuticals Holding AG
SIX:SANN
Intrinsic Value
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. [ Read More ]
The intrinsic value of one SANN stock under the Base Case scenario is 186.58 CHF. Compared to the current market price of 9.11 CHF, Santhera Pharmaceuticals Holding AG is Undervalued by 95%.
Fundamental Analysis
Balance Sheet Decomposition
Santhera Pharmaceuticals Holding AG
| Current Assets | 14.6m |
| Cash & Short-Term Investments | 12.7m |
| Receivables | 945k |
| Other Current Assets | 921k |
| Non-Current Assets | 65.2m |
| Long-Term Investments | 477k |
| PP&E | 1.2m |
| Intangibles | 63.1m |
| Other Non-Current Assets | 485k |
| Current Liabilities | 38.6m |
| Accounts Payable | 4.9m |
| Accrued Liabilities | 13.6m |
| Short-Term Debt | 14.2m |
| Other Current Liabilities | 6m |
| Non-Current Liabilities | 55.1m |
| Long-Term Debt | 25.8m |
| Other Non-Current Liabilities | 29.2m |
Earnings Waterfall
Santhera Pharmaceuticals Holding AG
|
Revenue
|
5.2m
CHF
|
|
Cost of Revenue
|
-3.6m
CHF
|
|
Gross Profit
|
1.5m
CHF
|
|
Operating Expenses
|
-48.3m
CHF
|
|
Operating Income
|
-46.7m
CHF
|
|
Other Expenses
|
-17.9m
CHF
|
|
Net Income
|
-64.7m
CHF
|
Free Cash Flow Analysis
Santhera Pharmaceuticals Holding AG
What is Free Cash Flow?
SANN Profitability Score
Profitability Due Diligence
Santhera Pharmaceuticals Holding AG's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Santhera Pharmaceuticals Holding AG's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
SANN Solvency Score
Solvency Due Diligence
Santhera Pharmaceuticals Holding AG's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Score
Santhera Pharmaceuticals Holding AG's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
SANN Price Targets Summary
Santhera Pharmaceuticals Holding AG
According to Wall Street analysts, the average 1-year price target for SANN is 30.6 CHF with a low forecast of 30.3 CHF and a high forecast of 31.5 CHF.
Shareholder Return
SANN Price
Santhera Pharmaceuticals Holding AG
| Average Annual Return | -40.23% |
| Standard Deviation of Annual Returns | 30.77% |
| Max Drawdown | -97% |
| Market Capitalization | 96.8m CHF |
| Shares Outstanding | 10 621 642 |
| Percentage of Shares Shorted |
N/A
|
Company Profile
Country
Industry
Market Cap
Dividend Yield
Description
Santhera Pharmaceuticals Holding AG engages in the development and commercialization of products for the treatment of neuromuscular and pulmonary diseases. The company is headquartered in Pratteln, Basel-Landschaft. The company went IPO on 2006-11-03. The firm is involved in the research, development and commercialization of pharmaceutical products for the treatment of neuromuscular and mitochondrial diseases. The Company’s products include Catena and Raxone brands, which are primarily implemented in the symptomatic treatment of Leber's Hereditary Optic Neuropathy (LHON) diseases. Sathera Pharmaceuticals Holding AG operates through its wholly owned subsidiaries: Santhera Pharmaceuticals (Schweiz) AG, Liestal, Santhera Pharmaceuticals (USA) Inc, Santhera Pharmaceuticals (Canada) Inc, Santhera Pharmaceutical (Deutschland) GmbH and Oy Santhera Pharmaceuticals (Finland) Ltd.
You don't have any saved screeners yet
